Age related decline in muscle function (sarcopenia) MedDRA version: 13.1 Level: PT Classification code 10063024 Term: Sarcopenia System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
Conditions
Interventions
Trade Name: Perindopril
Product Name: Perindopril 4mg
Product Code: Perindopril 4mg
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Perindopril
CAS Number: 107133-36-8
Current Sponsor code: Pe
Sponsors
University of Dundee
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: People aged 65 years or over with an impairment of mobility requiring the use of a walking aid and/or dependence in functional activities of daily living requiring assistance Short Physical Performance Battery (SPPB) score =10. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Already in receipt of ACE inhibitor or ARB Significant aortic outflow obstruction(gradient >30mmHg) eGFR 170umol/l Serum potassium >5.0mmol/l Systolic BP<90mmHg Previous diagnosis of heart failure Undiagnosed left ventricular systolic dysfunction on echocardiography Regular participation in exercise training Moderate to severe cognitive impairment (MMSE<20/30) Wheelchair bound (cannot perform outcomes) Unwilling to participate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Secondary Objective: Will those receiving the perindopril and exercise improve their self reported physical function and quality of life compared to those receiving the placebo and exercise?;Primary end point(s): The primary outcome measure is the change in the 6 minute walking distance over the 20 weeks between the two groups.;Main Objective: Will a medicine called perindopril augment the known benefits of exercise therapy on physical function in older people? We will ask participants to attend twice weekly, individually tailored group exercise classes for 10 weeks followed by home exercises for 10 weeks. Half the participants will receive perindopril and half will recive the placebo. We will ask participants to perform the physical function tests at baseline, 10 and 20 weeks to see those randomised to perindopril do better than those randomised to placebo. | — |
Countries
United Kingdom
Outcome results
None listed